Skip to main content

Table 4 Univariate and Multivariate Cox Regression for OS of breast cancer with liver metastases at diagnosis in the SEER database

From: Risk and prognostic factors of breast cancer with liver metastases

Variable

Overall Survival

Univariable

Multivariable

HR (95% CI)

P Value

HR (95% CI)

P Value

Age, y

 18–40

1[Reference]

 

1[Reference]

 

 41–60

1.52 (1.32–1.76)

< 0.001*

1.39 (1.20–1.61)

< 0.001*

 61–80

2.17 (1.88–2.51)

< 0.001*

1.84 (1.58–2.15)

< 0.001*

  > 80

4.44 (3.65–5.39)

< 0.001*

3.62 (2.76–4.74)

< 0.001*

Race a

 White

1[Reference]

 

1[Reference]

 

 Black

1.21 (1.09–1.33)

< 0.001*

1.35 (1.22–1.50)

< 0.001*

 Hispanic

0.99 (0.87–1.13)

0.895

1.16 (1.02–1.32)

0.028*

 Asian or Pacific Islander

0.86 (0.74–1.02)

0.078

0.90 (0.76–1.05)

0.182

 American Indian or Alaska Native

0.96 (0.58–1.59)

0.869

1.01 (0.60–1.68)

0.984

 Unknown

0.34 (0.09–1.37)

0.129

0.28 (0.07–1.15)

0.078

Marital status

 Unmarried a

1[Reference]

 

1[Reference]

 

 Married

0.75 (0.70–0.82)

< 0.001*

0.84 (0.77–0.91)

< 0.001*

 Unknown

0.96 (0.81–1.14)

0.664

0.89 (0.75–1.06)

0.200

Insurance status

 Uninsured b

1[Reference]

 

1[Reference]

 

 Insured

0.75 (0.62–0.91)

0.003*

0.71 (0.59–0.86)

< 0.001*

 Unknown

0.94 (0.68–1.30)

0.717

0.83 (0.57–1.22)

0.348

Histology

 Infiltrating duct carcinoma

1[Reference]

 

1[Reference]

 

 Lobular carcinoma

1.14 (0.97–1.34)

0.112

0.87 (0.74–1.03)

0.101

 Infiltrating duct and lobular carcinoma

0.94 (0.68–1.30)

0.717

0.89 (0.70–1.13)

0.323

 Other types c

1.43 (1.30–1.58)

< 0.001*

1.18 (1.05–1.33)

0.005*

Pathological Grade

 I

1[Reference]

 

1[Reference]

 

 II

1.08 (0.86–1.37)

0.515

1.35 (1.07–1.72)

0.013*

 III/IV

1.30 (1.04–1.64)

0.022*

1.69 (1.34–2.14)

< 0.001*

 Unknown

1.59 (1.26–1.01)

< 0.001*

1.59 (1.23–2.05)

< 0.001*

Surgery of primary site

 Yes

1[Reference]

 

1[Reference]

 

 No

1.72 (1.56–1.89)

< 0.001*

1.52 (1.38–1.68)

< 0.001*

 Unknown

0.93 (0.62–1.38)

< 0.001*

0.96 (0.64–1.43)

< 0.001*

Radiotherapy

 Yes

1[Reference]

 

1[Reference]

 

 No/Unknown

1.03 (0.94–1.12)

0.528

0.95 (0.87–1.04)

0.270

Chemotherapy

 Yes

1[Reference]

 

1[Reference]

 

 No/Unknown

2.03 (1.87–2.20)

< 0.001*

1.63 (1.50–1.78)

< 0.001*

Extrahepatic metastatic sites to lung, brain and bone, No

 0

1[Reference]

 

1[Reference]

 

 1

1.49 (1.34–1.65)

< 0.001*

1.42 (1.28–1.58)

< 0.001*

 2

1.94 (1.73–2.18)

< 0.001*

1.85 (1.65–2.09)

< 0.001*

 All 3

2.94 (2.44–3.56)

< 0.001*

3.43 (2.77–4.26)

< 0.001*

 Unknown

1.92 (1.62–2.28)

< 0.001*

1.62 (1.36–1.93)

< 0.001*

Subtype

 HR+/HER2−

1[Reference]

 

1[Reference]

 

 HR+/HER2+

0.59 (0.53–0.66)

< 0.001*

0.69 (0.61–0.77)

< 0.001*

 HR−/HER2+

0.72 (0.63–0.82)

< 0.001*

0.85 (0.74–0.97)

0.014*

 Triple-negative

2.10 (1.88–2.35)

< 0.001*

2.46 (2.18–2.77)

< 0.001*

 Unknown

1.54 (1.36–1.74)

< 0.001*

1.38 (1.20–1.58)

< 0.001*

  1. Notes: a including divorced, separated, single (never married), and widowed; b including insured, Insured/No specifics Any Medicaid; c including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma;
  2. + denotes positive; − denotes negative; * denotes a statistically significant P-value; HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, OR Odds ratio, CI Confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us